Congress Partners

Journal Partners

Cancer Drug Resistance (CDR) stands as an international, open-access, and peer-reviewed journal, meticulously curated for researchers in the dynamic realm of cancer drug resistance. Recognized by prestigious indices such as ESCI, PMC, and Scopus, CDR achieved its inaugural impact factor (IF: 3.7) in June 2023, setting a benchmark for excellence in the field. As a trailblazer, it remains the sole continuously published journal exclusively devoted to cancer drug resistance, ensuring swift dissemination of cutting-edge, peer-reviewed original research. Our scope encompasses a diverse range, including research articles, reviews, case reports, commentaries, and letters, elucidating pharmacological facets of drug resistance and its reversal. From drug design to delivery and cellular drug resistance, CDR explores pivotal dimensions. Embracing openness, all contributions are published under the CC BY 4.0 Agreement, underscoring our commitment to fostering a collaborative and insightful scientific community. Explore the latest advancements at our journal website: https://www.oaepublish.com/cdr
 

 
Media Partners

 

Skip to content